• Final patient dosed in the phase I study • Production process of SOL-116 according to plan • Adjusting the WACC leads to a new fair value of SEK 15.19 (10.81) per share
ANNONS
During the third quarter, Lipum reported continued progress in its clinical programme with the drug candidate SOL-116 in rheumatoid arthritis (RA). Most significantly, the last patient in the ongoing phase I study was included and dosed. This means all participants and patients have been included and the study advances towards completion.
In summary, the model changes have led to a higher fair value, SEK 15.19 (10.81) per share.
